CAROLYN SMALLWOOD: Open Payments
NPI 1578004552 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,293 in 106 payments from 21 companies in 2025. Trend: 2023 $2,072 · 2024 $3,146 · 2025 $2,293
Food & beverage: $2,293
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $398 |
| Novartis Pharmaceuticals Corporation | 11 | $220 |
| TG Therapeutics, Inc. | 8 | $187 |
| UCB, Inc. | 6 | $184 |
| Mallinckrodt Hospital Products Inc. | 8 | $160 |
| Genentech USA, Inc. | 7 | $153 |
| Biogen, Inc. | 10 | $148 |
| Eisai Inc. | 5 | $126 |
| Amgen Inc. | 5 | $116 |
| ABBVIE INC. | 6 | $94 |
Products named: INGREZZA, KESIMPTA, BRIUMVI, Rystiggo, ACTHAR, TYSABRI, Ocrevus, Leqembi.
Industry payments across AL — which companies pay providers there.
